Navigation Links
Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study

ALBUQUERQUE, N.M., Oct. 23 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD), a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer. The next stage of the Phase II trial calls for Biomoda to begin testing samples from already-diagnosed lung cancer patients in accordance with the study protocol approved by the U.S. Food and Drug Administration (FDA).

"More than 500 veterans volunteered to be screened with the Biomoda assay. It has been heartening to see so many men and women who served their country in the armed forces willing to help once again by participating in this important study," said John Cousins, President of Biomoda. "The study is not complete, but we are pleased with the progress to date and expect to have final data in the first half of 2010."

The Biomoda diagnostic, trademarked under the name CyPath®, is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is screened for cancer cells with both the CyPath® assay and traditional Pap staining. Participants also undergo a CT scan.

Dr. Thomas Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware, is the Principal Investigator overseeing the Phase II clinical trial. He has lead several lung and esophageal cancer studies and heads up Christiana's participation in the International Early Lung Cancer Action Program (I-ELCAP).

Based in Albuquerque, NM, Biomoda is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer.

SOURCE Biomoda, Inc.

SOURCE Biomoda, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Lab Products Magazine Features Biomoda
2. FDA Reviewing Biomoda Submission for Cancer Screening Study
3. Small Business Innovation Research Program Awards Grant to Biomoda
4. Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting
5. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
8. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
9. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
10. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
Breaking Medicine News(10 mins):